Clinical-stage RNAi company RXi Pharmaceuticals Corporation recently announced it had received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for both the composition of matter and methods of use for its self-delivering RNAi (sd-rxRNA®) compounds targeting connective tissue growth factor (CTGF).
The patent reportedly includes RXi's lead clinical candidate, RXI-109, which is currently being evaluated in multiple clinical trials to reduce scar formation in the eye and skin. According to the company, a Phase 1/2 clinical study is currently underway to evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring.
Click here to read the full press release.
And RXi also announced it would be presenting at the Association for Research in Vision and Ophthalmology (ARVO) 2016 annual meeting. The company will reportedly present new data from ongoing research using RXi's proprietary RNAi platform in the area of therapeutic topical delivery to the eye at the 3:15 to 5 pm PDT poster session Corneal Wound Repair and Healing on Sunday, May 1, 2016.
Click here to read the full press release.
Source: RXi Pharmaceuticals Corporation